WHAT IS TARGETED NUTRITIONAL INTERVENTION 

IMG_0123

Targeted Nutritional Intervention (TNI) is based solely on peer reviewed, published research. The rationale, that upregulated genes can be inhibited by natural substances, has been proven repeatedly. In fact, down regulation, or inhibition, of over expressed genes is the goal of most pharmaceutical trials.  We believe this goal can be accomplished safer, less expensively and with greater effectiveness through nutrients.

Generally, pharmaceuticals only target one gene, neurotransmitter or pathway at a time. To date, no drug has been studied successfully in human beings, though several seemed promising in animal trials. However, a number of natural substances have been proven successful in combatting various aspects of Down syndrome. In order to effectively treat Down Syndrome many genes, neurotransmitters and proteins must be addressed. Down Syndrome is a multifaceted disorder involving numerous neurological, physical and metabolic disturbances. No single drug will ever be able to address all or even the majority of these issues. They are far too dissimilar and pharmaceuticals are limited in focus. That is not an issue with nutrients as even if a vitamin or amino acid targets only one gene, nutrients targeting dozens of others can be blended together. In fact the synergy of nutrients makes a combined supplement even more effective.

Our genes were created to interact with proteins found in foods. Human cells rely upon nutrients, including vitamins, minerals, amino acids and polyphenols to function properly. A good example is folate. Folic acid is inactive when first consumed. It is of no benefit to the human body whatsoever without vitamin B12. Human life cannot exist without folate. Even though bacteria in the gut can synthesis B12, it is not enough. We must obtain it from our diets. (Citation 1.)

“Gene expression is controlled by multiple molecular systems, which become more elaborate as one moves up the evolutionary chain. Transcription factors are proteins that bind to specific DNA sequences, working either independently or in a concerted fashion. Further, chromatin remodeling can allow or prevent transcriptional apparatuses from navigating to their binding sites on DNA.” (Citation 2.)

All of this complex activity occurs twenty four hours a day in three trillion human cells without the necessity of a single solitary drug. Everything ultimately depends upon the nutrients found in food.

Several drug trials have recently failed to produce desirable results. Why is that? We believe the complexity of the neurobiochemistry of Down Syndrome greatly interferes with a single target drug. Altered biochemistry is like standing dominoes on their ends. You touch one and the rest topple. In a similar manner, the additional genes that are encoded to the Down Syndrome Critical Region of chromosome 21 effect genes and their enzymes and proteins all across the entire genome. Just as it is impossible to stand a domino on its end in the middle of a cascade and expect those still toppled over to suddenly right themselves, so is it highly unlikely a single target drug could ever right the multiple genes effecting the brain. Multiple drugs would have to be developed, as many as several dozen and the feasibility of such a therapy is remote. It would be difficult, if not impossible, to counter the numerous side effects that would likely occur.

The combination of vitamins, amino acids, minerals and flavonoids, each selected to either target a specific gene or for its specific requirement to address the unique biochemistry of Down syndrome, provides the best possible option for therapy.

 

TARGETING NEUROTRANSMITTERS